Table 2.
Summary of relative risks of LPDs occurring after MCC.
| Reference | Country (Years of Registry) | Type of LPD | No. of MCC Patients | No. (%) of LPDs After MCC Diagnosis | SIR a | 95% CI |
|---|---|---|---|---|---|---|
| Howard et al. 2006 [22] | USA (1986–2002) | NHL | 1306 | 10 (0.77%) | 2.56 | 1.23–4.71 |
| Koljonen et al. 2010 [100] | Finland (1979–2006) | NHL | 172 | 2 (1.2%) | 4.52 | 0.55–16.3 |
| Bzhalava et al. 2012 [111] | Denmark, Norway, Sweden (1980–2007) | NHL | 756 | 1 (0.13%) | 0.7 | 0.1–4.97 |
| Howard et al. 2006 [22] | USA (1986–2002) | CLL | 1306 | 3 (0.23%) | 2.72 | 0.55–7.94 |
| Heath et al. 2008 [24] | USA (1980–2007) | CLL | 195 | 8 (4.1%) |
48 (≤70 y old)
34 (≥70 y old) |
-- |
| Koljonen et al. 2010 [100] | Finland (1979–2006) | CLL | 172 | 2 (1.2%) | 17.9 | 2.16–64.6 |
| Kaae et al. 2010 [15] | Denmark (1978–2006) | CLL | 185 | 2 (1.1%) | 11 | 2.7–43.8 |
| Tadmor et al. 2012 [110] | Israel (1989–2010) | 45% CLL 29% NHL 6% other | 335 | M: 4 F: 3 N = 7 (2.1%) | M: 3.57 F: 2.94 | M:0.07–7.07
F: 0.00–6.27 |
Abbreviations: CLL, chronic lymphocytic leukemia; F, female; LPD, lymphoproliferative disorder; M, male; MCC, Merkel cell carcinoma; NHL, non-Hodgkin lymphoma; SIR, standardized incidence ratio; USA, United States of America. a Statistically significant risk values are shown in boldface type.